Fate Therapeutics Inc (FATE)

[jondoeuk]

A post on LinkedIn (by Alex Shih-Min Huang who is VP, Head of Cell Therapy at BGNE): ''Though our very first experiment was initiated only 2.5 years ago amidst ongoing laboratory construction and pandemic, fast forward to this day, we have already 1) generated a proprietary, well-characterized GMP grade iPSC clone collection designated for our future gd T and ab T cellular products, 2) established our unique efficient, enrichment-free, feeder-free methodologies that deliver impressively high purity and high expansion fold for our iPSC derived gd T and iPSC derived CD8 ab T platforms, and 3) engineered proprietary genetic elements that further enhance the longevity and potential efficacy of our effector cell populations. Our platforms are designed to allow plug-and-play for a variety of CAR-T and TCR-T cell therapies with potential to address unmet needs in diverse indications.''